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INTRODUCTION: In the postmenopausal period, an average of 25% of women will present symptomatic ovarian
failure requiring hormonal replacement therapy. Estrogen can relieve vasomotor symptoms. Hormonal replacement therapy
is generally not recommended for breast cancer patients due to the potential risk of tumor recurrence. To answer the
questions about the safety of hormonal replacement therapy in this subgroup of women, it is necessary to establish the
acceptance of treatment.
METHODS: Between September 1998 and February 2001, a cohort of 216 breast cancer patients were asked to
complete a questionnaire. All patients had completed their treatment and were informed about survival rates after breast
cancer and hormonal replacement therapy.
RESULTS: Among the 216 patients, 134 (62%) would refuse hormonal replacement therapy. A hundred patients were
afraid of relapse (74.6%). Adjuvant tamoxifen therapy was the only statistically significant variable (70.3% versus 29.7%
p=0.003). Understanding clinical stage (p= 0.045) and type of medical assistance (private versus public , p=0.033) also
seemed to influence the decision. Early stage disease (p= 0.22), type of surgical procedure (radical versus conservative,
p=0.67), adjuvant chemotherapy (p=0.082) or marital status (p=0.98 ) were not statistically significant in decision making.
Several patients submitted to adjuvant chemotherapy (41.6%) would accept hormonal replacement therapy under medical
supervision, as did most of advanced clinical stage patients (58.3%; p=0.022).
CONCLUSION: There is a high level of rejection for hormonal replacement therapy among breast cancer patients
when current data on tumor cure rates, and potential risks of estrogen use is available. Adverse effects of tamoxifen in the
adjuvant setting may be the reason for refusal of hormonal replacement therapy .
DESCRIPTORS: Breast cancer. Hormone replacement. Tamoxifen.
INTRODUCTION
Frequent and intense vasomotor
symptoms can be responsible for a sig-
nificant deterioration in the quality of
life of postmenopausal women 1. Hor-
mone replacement therapy (HRT) with
estrogen has been used for many dec-
ades for managing menopausal symp-
toms and urogenital dysfunction as
well as for reducing the morbidity and
mortality related to osteoporosis and
cardiovascular disease 2-6. Despite the
fact that HRT has demonstrably im-
proved the quality of life in healthy
postmenopausal women; few observa-
tional studies 7-10 have approached this
therapy in breast cancer treated pa-
tients, and none of them have ob-
served either increased disease recur-
rence or mortality.
Early detection and improved
therapies have shown a positive effect
on life expectancy in breast cancer pa-
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tients. As overall and disease- free sur-
vival improves, quality of life be-
comes more important, mostly in those
patients who have low- risk breast can-
cer and experience menopausal symp-
toms earlier than expected due to an-
tineoplastic treatment.
Based on observational studies 11-
14 reporting a small, but increased risk
of breast cancer, HRT is generally not
recommended for breast cancer pa-
tients succesfully treated, since its ef-
fects on the risk of tumor recurrence
remains uncertain.
On the other hand, an increasing
number of younger patients, who have
completed treatment for low- risk
breast cancer, will face many years of
estrogen deficiency and impaired qual-
ity of life. These patients are therefore
potential candidates for HRT, since
death from nonneoplastic conditions is
common among node-negative breast
cancer survivors 15. In the1997´s con-
sensus conference about treatment of
estrogen deficiency symptoms in
women surviving breast cancer, there
was an agreement upon the need to
conduct trials to evaluate HRT in se-
lected groups of patients 16. Thus, we
have conducted this study to analyze
the acceptance of HRT in patients pre-
viously treated for breast cancer.
METHODS
Between September, 1998 and
February, 2001; 216 women treated for
breast cancer were interviewed. All pa-
tients have completed their treatment
and were in the follow-up period. Eli-
gibility criteria included histological
diagnosis of breast cancer; female sex;
completion of breast cancer treatment
(surgery, chemotherapy and hormonal
therapy); no clinical or radiological
evidence of metastatic disease and 18
years of age or older. After signing the
informed consent, all patients received
three cards with the following informa-
tion: clinical menopause symptoms,
benefits of HRT, cure rates for early
stage breast cancer, HRT and breast
cancer risk, data on relationship be-
tween nodal stage and risk of recur-
rence, and a literature overview on
HRT and breast cancer. A questionnaire
was then applied by the research
nurse. The patients were questioned
about use of HRT at the time of the
study, presence of menopause symp-
toms and related morbidities (cardio-
vascular diseases, bone fractures),
tumor’s clinical stage, previous use of
hormones and acceptance of HRT. Sta-
tistical analyses were performed by
univariate and multivariate logistic re-
gression models to evaluate the rela-
tionship concerning HRT acceptance,
as well as the independent variables.
The study was approved by the inter-
nal Institutional Review Board.
RESULTS
All patients had completed their
treatment and were informed about
survival rates after breast cancer and
HRT. Patients’ characteristics and re-
sults are shown in table 1.
Among the 216 patients, 134
(62%) refused HRT. The main reason
was the fear of relapse (74.6%). The
use of adjuvant tamoxifen citrate
therapy was the only statistically sig-
nificant variable (70.3% versus 29.7%;
p=.003 log rank). Refusal was more
pronounced among patients who did
not know their clinical stage when
compared to those who did know
(78.6% versus 59.6%; p=0.045 log
rank). Type of medical assistance (pri-
vate versus public, 68.3% versus
54.1%, respectively; p=0.033 log rank)
also seemed to influence the decision.
The majority of patients had early
stage disease (75.9%), and we ob-
served a tendency to accept HRT
among those with advanced stage, al-
though without statistical significance
(58.3% versus 37.8%; p=0.22 log
rank). Type of surgical procedure (radi-
cal mastectomy versus conservative
therapies, p=0.67 log rank), adjuvant
chemotherapy (p=0.082 log rank) or
marital status (p=0.98 log rank) were
also not statistically significant in the
Table 1 -  Patients characteristics and acceptance of hormonal replacement therapy.
Hormonal Replacement Therapy. p value
Yes No
Prior treatment
Surgery .678
Radical mastectomy 38 066
Conservative 44 068
Chemotherapy .082
Yes 64 090
No 18 044
Hormone therapy (adjuvant) .003
Yes 38 090
No 44 044
Hormone therapy (others) .035
Yes 46 080
No 36 048
Type of health ensurance .033
Public 44 052
Private 38 082
Knowledge of Clinical Stage .045
Yes 76 112
No 0 6 022
Clinical Stage .022
Inicial 62 102
Advanced 14 010
Unknown 0 6 022
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decision-making process. Previous
hormone therapy was only marginally
significant in refusal. Hormones were
used as contraceptives (24.1%), treat-
ment for irregular menses (5.6%), and
endometriosis (1.9%). Twenty-four
percent of women ignored the reasons
for its use. Among the 126 users,
63.5% would not accept HRT com-
pared to 57.1% of non-users (p=0.35
log rank).
DISCUSSION
Our study has analyzed the accept-
ance of HRT among women who have
completed their treatment for breast
cancer. This is a subgroup of women
in which menopause symptoms can
begin earlier in life due to treatment
induced ovarian failure, and will be
exposed to the deleterious effects of
hormone deprivation, since HRT is
generally not indicated. Although the
majority of the patients analyzed in
this study were afraid that HRT might
lead to cancer recurrence, some of them
(38%) would accept such therapy to
control menopause symptoms, and late
effects like osteoporosis. The fact that
patients with advanced disease would
consider taking HRT seems paradoxi-
cal. One could say that once the dis-
ease was advanced, it could not grow
worse with the use of HRT, and these
patients were probably more con-
cerned about quality of life rather than
survival extension. One of the survey’s
end-points was to analyze if the type
of breast cancer treatment would influ-
ence the acceptance of HRT. The sur-
vey results suggest that previous hor-
monal treatment, specially adjuvant
tamoxifen citrate, affects patients’ at-
titudes toward HRT. The statistically
significant impact that previous use of
tamoxifen citrate had on acceptance of
HRT may be associated to some of its
side effects and duration of treatment,
during which patients were reminded
most of the time that they were taking
a hormonal blocker. Few patients had
no knowledge about their clinical
stage or previous use of any hormonal
manipulation, and that may have been
the reason for increased refusal among
them (78.6% p=0.045 and 100% p=
0.035% log rank; respectively). The
absolute refusal among patients who
did not know about previous exposure
to hormones seems to reflect the un-
certainty about a possible connection
between them and their tumors’ devel-
opment. Hence it is understandable
that they would not accept the risks of
relapse by using HRT. These findings
probably reflect the importance that
correct information about disease, and
the exposure to potential risk factors
has on decision-making among breast
cancer patients.
The hypothesis that estrogen is a
promoter of breast cancer is based on
epidemiological, clinical and experi-
mental studies 13,17-19. Epidemiological
studies have shown a positive associa-
tion between breast cancer and HRT.
The Collaborative Group on Hormo-
nal Factor in Breast Cancer reanalyzed
data from 53,865 postmenopausal
women, of whom 17,830 (33%) had
used HRT at some time. A relative risk
(RR) of having breast cancer of 1.35
(2p=0.00001) for those who used HRT
for 5 years or longer was found, but
cancers diagnosed in women who had
ever used HRT tended to be less ad-
vanced clinically. The estimated risk
of breast cancer increased by 2.3%
(95%CI= 1.1% to 3.6%; p=. 0002) for
each year of postmenopausal use of
HRT 13.
In the prospective cohort of more
than 120.000 postmenopausal women
(The Nurse’s Health Study), the relative
risks of breast cancer incidence ranged
from 1.09 to 1.47, but the RR of death
from breast cancer for current HRT us-
ers was 0.76, suggesting that HRT ap-
pears to be associated with a greater
risk for breast cancer development than
for death due to the neoplasia per se 2.
Although there are some evidences
that estrogen could negatively affect
breast cancer incidence, HRT did not
increase cancer recurrence or mortality
when 2755 women diagnosed with in-
vasive breast cancer were analyzed by
O´Meara et al. 20. The relative risks of
cancer recurrence, cancer mortality and
overall mortality in women who used
HRT after breast cancer diagnosis
compared to those who did not use it
were 0.50 (95% CI= 0.30 to 0.85), 0.34
(95% CI= 0.13-0.91) and 0.48 (95%
CI= 0.29 to 0.78), respectively; sug-
gesting that HRT after breast cancer
has no adverse impact on recurrence
and mortality.
Since the cause of death among
node- negative breast cancer patients
is associated with non-neoplastic con-
ditions, HRT could have a positive ef-
fect on overall survival.
Nevertheless, based on the results
obtained from randomized trials such
as HERS trial 21, which found no over-
all cardiovascular benefit of HRT in
postmenopausal women with stable
coronary heart disease (CHD), and the
estrogen replacement and atheroscle-
rosis (ERA) trial 22 showing that HRT
did not slow the progression of athero-
sclerosis in patients with a history of
coronary stenosis; the American Heart
Association has advised against the
use of HRT alone for secondary pre-
vention of cardiovascular disease in
postmenopausal women 23. Selection
bias including age of subjects, sever-
ity of CHD and “health user” effect
may explain the poor outcome ob-
served in the HERS trial. In addition,
the EPAT study (Estrogen in the Pre-
vention of Atherosclerosis Trial) have
found different results from those of
the ERA trial. In this randomized
estrogen-placebo trial, the rate of pro-
gression of subclinical atherosclerosis
was slower in postmenopausal women
taking HRT 24. Probably only the re-
sults from the prospective placebo-
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controlled trial (The Women´s Health
Initiative Study), expected to recruit
over 25,000 postmenopausal women
will answer the question about the in-
fluence of HRT on primary CHD end
points and overall mortality 25.
The observation of an increasing
number of women at younger age di-
agnosed with invasive breast cancer
who expected to suffer early treatment
induced menopause, have motivated
some series of HRT in these subset of
patients. Available data indicate that
HRT does not seem to adversely affect
breast cancer outcome 7-10. Among 319
women with breast cancer followed
prospectively, there was only one
breast cancer event in the HRT group
against 20 in the control group 10. A
systematic literature review of 11 stud-
ies also showed a RR of breast cancer
recurrence of 0.82 26.
Patients with breast cancer who were
using replacement estrogens at the time
of diagnosis experienced reductions in
breast cancer mortality 2,27. HRT does not
seem to have an adverse effect on diag-
nosis and outcome of early-stage inva-
sive breast cancer when treated with con-
servative surgery and radiation. In addi-
tion, previous history of HRT have not
been associated with increased risk of
contralateral breast cancer or second non-
breast cancer malignancy 28.
Our results are similar to those
found by Vassilopoulo-Sellin et al. 29
in a cohort of 224 patients where prior
treatment, menopausal status, and
symptoms affected patients attitudes
toward HRT. Most concerns were the
menopause-related risk of osteoporo-
sis (70%) heart disease (72%) and
cancer recurrence (78%) due to HRT
use; although 44% of menopausal
women would consider HRT under
medical supervision.
While discussing menopause man-
agement, the potential risks of cancer
recurrence and benefits of HRT must
be taken into account when patients
have a history of breast cancer. Most
of all, it is necessary to identify pa-
tients needs and concerns. Although
quality of life could be improved by
HRT, that strategy should be consid-
ered with caution, in an investigational
clinical setting, until a randomized,
prospective controlled trial on the im-
pact of HRT in breast cancer patient’s
survival is available.
RESUMO
ANELLI A e col. - Terapia de reposi-
ção hormonal e o risco de câncer
de mama: avaliação de atitudes em
pacientes previamente tratadas por
câncer de mama. Rev. Hosp. Clín.
Fac. Med. S. Paulo 58(2):91-96
2003.
INTRODUÇÃO: Cerca de 25% das
mulheres apresentarão deficiência
estrogênica sintomática necessitando
terapia de reposição hormonal. A uti-
lização de terapia de reposição hor-
monal diminui os sintomas vaso-
motores e outras morbimortalidades. A
terapia de reposição hormonal geral-
mente não é recomendada para as pa-
cientes com câncer de mama, devido
o possível aumento no risco de recor-
rência. Para responder às questões so-
bre a segurança da terapia de reposi-
ção hormonal neste subgrupo de mu-
lheres, é necessário estabelecer a acei-
tação do tratamento.
MÉTODO: Entre setembro de
1998 e fevereiro de 2001, 216 pacien-
tes foram submetidas a um questioná-
rio auto-aplicável. As pacientes havi-
am encerrado o tratamento antineo-
plásico e, receberam informações sobre
as taxas de sobrevida após câncer de
mama e terapia de reposição hormonal.
RESULTADOS: Entre as 216 pa-
cientes, 134(62%) não fariam terapia
de reposição hormonal. Cem pacientes
receavam uma recorrência (74,6%).
Tamoxifeno adjuvante foi a única va-
riável estatisticamente significativa
(70,3% versus 29,7% p=0,003). Co-
nhecimento do estádio clínico (p=
0,045) e tipo de assistência médica
(privada versus pública , p=0,033) pa-
recem influenciar a decisão. Estádio
inicial (p= 0,22), tipo de cirurgia (ra-
dical versus conservadora, p=0,67),
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quimioterapia adjuvante (p=0,082) ou
estado civil (p=0,98) não foram esta-
tisticamente significativos. Várias pa-
cientes submetidas à quimioterapia
adjuvante (41,6%) aceitariam terapia
de reposição hormonal sob supervisão
médica, assim como a maioria das pa-
cientes com doença avançada (58,3%;
p=0,022).
DISCUSSÃO: Foi observada uma
alta taxa de rejeição à terapia de repo-
sição hormonal entre as pacientes
quando informações atualizadas sobre
taxas de cura, e potenciais riscos do
uso de estrógeno estão disponíveis.
Efeitos adversos associados ao tamo-
xifeno adjuvante poderiam estar rela-
cionados à maior recusa .
DESCRITORES: Câncer. Mama.
Reposição hormonal. Tamoxifeno.
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